Cytotoxic effects of the compound cis-tetraammine (oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells

Página do item simplificado
dc.creatorPereira, Flávia de Castro
dc.creatorLima, Aliny Pereira de
dc.creatorVilanova-Costa, Cesar Augusto Sam Tiago
dc.creatorPires, Wanessa Carvalho
dc.creatorRibeiro, Alessandra de Santana Braga Barbosa
dc.creatorPereira, Lucas Carlos Gomes
dc.creatorPavanin, Luiz Alfredo
dc.creatorSantos, Wagner Batista dos
dc.creatorLacerda, Elisângela de Paula Silveira
dc.date.accessioned2018-08-28T11:42:43Z
dc.date.available2018-08-28T11:42:43Z
dc.date.issued2014
dc.description.abstractChemotherapy is a common treatment for leukemia. Ruthenium complexes have shown potential utility in chemotherapy and photodynamic therapy. The identification of new chemotherapeutics agents is critical for further progress in the treatment of leukemia. Ruthenium complexes generally have lower toxicities compared to cisplatin attributed to their specific accumulation in cancer tissues. Based on these evidences, in the present work we studied the cytotoxic activity of the ruthenium(III) compound cis-tetraammine(oxalato)ruthenium(III) dithionate - {cis-[Ru(C 2 O 4 ) (NH 3 ) 4 ] 2 (S 2 O 6 )} against human chronic myelogenous leukemia cells (K-562) tumor cell line. The tested compound induces cell death in a dose and time dependent manner on K-562 cells. It is found that the effect was improved linearly while prolonging the incubation time. Compared to the cell cycle profiles of untreated cells, flow cytometric analysis indicated the sub-G1 arresting effect of ruthenium compound on K-562 cells. In our study, {cis-[Ru(C 2 O 4 )(NH 3 ) 4 ] 2 (S 2 O 6 )} shows a significant increase in tailed cells in any of the concentrations tested compared with negative control. Consequently, the concentration of {cis-[Ru(C 2 O 4 )(NH 3 ) 4 ] 2 (S 2 O 6 )} might be associated cytotoxicity with direct effect on K-562 cells DNA. Thus, it can be deducted that ruthenium-based compounds present selectivity to enter both tumor and normal cells. Additional studies are needed to determine the molecular mechanisms of the active components and to evaluate the potential in vivo anticancer activity of the cis-tetraammine(oxalato)ruthenium(III) dithionate.pt_BR
dc.identifier.citationPEREIRA, Flávia de Castro; LIMA, Aliny Pereira de; VILANOVA-COSTA, Cesar Augusto Sam Tiago; PIRES, Wanessa Carvalho; RIBEIRO, Alessandra de Santana Braga Barbosa; PEREIRA, Lucas Carlos Gomes; PAVANIN, Luiz Alfredo; SANTOS, Wagner Batista dos; SILVEIRA-LACERDA, Elisângela de Paula. Cytotoxic effects of the compound cis-tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells. SpringerPlus, London, v. 3, n. 301, p. 1-10, 2014.pt_BR
dc.identifier.doi10.1186/2193-1801-3-301
dc.identifier.issne- 2193-1801
dc.identifier.urihttp://repositorio.bc.ufg.br/handle/ri/15759
dc.language.isoengpt_BR
dc.publisher.countryGra-bretanhapt_BR
dc.publisher.departmentInstituto de Ciências Biológicas - ICB (RG)pt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectApoptosispt_BR
dc.subjectCis-tetraammine(oxalato)ruthenium(III) dithionatept_BR
dc.subjectCytotoxic activitypt_BR
dc.subjectK-562pt_BR
dc.subjectRuthenium(III) compoundspt_BR
dc.subjectImmunomodulatory activitypt_BR
dc.subjectApoptosispt_BR
dc.titleCytotoxic effects of the compound cis-tetraammine (oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cellspt_BR
dc.typeArtigopt_BR

Arquivos

Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Artigo - Flávia de Castro Pereira - 2014.pdf
Tamanho:
836.66 KB
Formato:
Adobe Portable Document Format
Baixar
Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Baixar

Coleções

ICB - Artigos publicados em periódicos